Abstract: Objective 　To evaluate clinical and pathological significance of HER2 and HER3 in Non-small-cell lung cancer (NSCLC) tissue. Methods 　Sixty-one patients with NSCLC were enrolled in the study. Tumor tissue specimens were collected to determine HER2/ HER3 status by immunohistochemist ry (SP methods) . Results 　Among the 61 patient s, the positive expressing rates of HER2 and HER3 were 50.8 % and 18. 0 %, respectively. The expressing rates of HER2 were significantly higher than that in the non-cancer specimens ( P < 0. 05) . The HER2 expressing rate was much higher in female 、adenoma 、non-smokers than that of the corresponding cont rol group s, but no differences were found the correlation between HER2 expressing status and clinical characteristics. No differences were found the correlation between HER2 expressing status and HER3 expressing status. Conclusion 　It is positive expressing of HER2 and HER3 that exist s in NSCLC tissue ;only function of HER2 was limited in non-small cell lung cancer ; the function of combination HER2 and HER3 protein may need to study in development of NSCLC.